GlassScriptPhysician profile
Kelvin E Yeh
NPI 1104063940
$5,575.15
in general payments reported to CMS, 2019-2025
20 companies · $1,528 in 2025
The $1,528 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,160 · 2020: $218 · 2021: $399 · 2022: $623 · 2023: $625 · 2024: $1,022 · 2025: $1,528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,175.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,308.41 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,285.58 | 2019-2025 | Rinvoq, Skyrizi |
| Ardelyx, INC. | $705.16 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $390.84 | 2019-2024 | Dificid |
| Janssen Biotech, INC. | $326.42 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $312.74 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $275.91 | 2019-2025 | |
| Pfizer INC. | $156.97 | 2019-2025 | |
| Novo Nordisk INC | $144.62 | 2025 | Wegovy |
| Allergan, INC. | $124.48 | 2019 | |
| Qol Medical, LLC | $122.64 | 2019-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $112.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $72.67 | 2019-2025 | Rebyota |
| Braintree Laboratories, INC. | $72.46 | 2019-2025 | Suflave, Sutab |
| Takeda Pharmaceuticals U.S.A., INC. | $61.96 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $31.11 | 2023 | Syfovre |
| Ironwood Pharmaceuticals, INC | $22.93 | 2019 | |
| Redhill Biopharma INC. | $16.25 | 2020 | |
| Shionogi INC | $16.10 | 2019 | |
| B. Braun Interventional Systems INC. | $15.88 | 2025 | Spectraline |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelvin Yeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.